Euglycemic Ketoacidosis Induced by Dapagliflozin in a Non‐Diabetic Patient With Cardiac Amyloidosis

Clinical Case Reports 2026 Open access

Read full text
Authors: Salhamoud Abdelfatah Saleh Hamoud, Ellie Harding
DOI: 10.1002/ccr3.71818
Cited by: 1
References: 9

Abstract

Dapagliflozin, though beneficial in heart failure, can rarely cause euglycemic ketoacidosis even in non-diabetic patients. Clinicians should maintain a high index of suspicion for metabolic acidosis in patients on SGLT2 inhibitors presenting with unexplained illness, regardless of blood glucose level.

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Diabetes Treatment and Management Diabetes and associated disorders

Publication details

Journal / source
Clinical Case Reports
Publisher
Wiley
Volume
14
Issue
1
Pages
e71818–e71818
Publication date
1 January 2026
Language
EN